Engström G, Hedblad B, Janzon L, et al. 2007. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population- based cohort study. Eur J Cardiovasc Prev Rehabil, 14:392–7. Fattouch K, Bianco G, Speziale G, et al. 2007. Beneﬁcial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patient who underwent surgical reperfusion: a randomised double-blind study. Eur J Cardiothorac Surg, 32:326–32. Fitch JC, Rollins S, Matis L, et al. 1999. Pharmacology and biological efﬁcacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation, 100:2499–506. Flexner S, Noguchi H. 1903. Snake venom in relation to hemolysis, bacteriolysis and toxicity. J Exp Med, 6:277–301. Fosse E, Thelin S, Svennevig JL, et al. 1997. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: a European multicentre study. Eur J Cardiothorac Surg, 11:320–7. Fujii S, Hitomi Y. 1981. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein, and trypsin. Biochim Biophys Acta, 661:342–45. Fu J, Lin G, Wu Z, et al. 2006a. Anti-apoptotic role for C1 inhibitor in ischemia/reperfusion-induced myocardial cell injury. Biochem Biophys Res Commun, 349:504–12. Fu J, Lin G, Zeng B, et al. 2006b. Anti-ischemia/reperfusion of C1 inhibitor in myocardial cell injury via regulation of local myocardial C3 activity. Biochem Biophys Res Commun, 350:162–8. Gewurz H, Clark DS, Cooper MD, et al. 1967. Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation, 5:1296–303. Gold B, Merriam JE, Zernant J, et al. 2006. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet, 38:458–62. Granger CB, Mahaffey KW, Weaver WD, et al. 2003. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement Inhibition in Myocardial Infarction treated with Angioplasty (COMMA) trial. Circulation, 108:1184–90. Griselli M, Herbert J, Hutchinson WL, et al. 1999. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med, 190:1733–40. Halas YA, Rahal E, Abdelnoor AM, et al. 2005. Serum C-reactive protein and complement proteins in patients with acute myocardial infarction. Immunopharmacol Immunotoxicol, 27:405–16. Haines JL, Hauser MA, Schmidt S, et al. 2005. Complement factor H variant increases the risk of age-related macular degeneration. Science, 308:419–21. Hansson GK, Holm J, Kral IG. 1984. Accumulation of IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions. Acta Pathol Microbiol Immunol Scand A, 92:429–35. Harris CL, Williams AS, Linton SM, et al. 2002. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol, 129:198–207. Haverich A, Shernan SK, Levy JH, et al. 2006. Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg, 82:486–92. Higgins PJ, Ko JL, Lobell R, et al. 1997. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I co-factor activities. J Immunol, 158:2872–81. Hill A, Hillmen P, Richards SJ, et al. 2005a. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood, 106:2559–65. Hill A, Richards SJ, Hillmen P. 2007. Recent developments in the understanding and management of paroxysmal nocturnal hemoglobinuria. Br J Haematol, 137:181–92. Hill A, Ridley SH, Esser D, et al. 2006. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood, 107:2131–7. Biologics:Targets & Therapy 2008:2(4) Anticomplement therapy Hill A, Rother RP, Hillmen P. 2005b. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Haematologica, 90:ECR40. Hillmen P, Hall C, Marsh JC, et al. 2004. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med, 350:552–9. Hillmen P, Lewis SM, Bessler M, et al. 1995. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med, 333:1253–8. Hillmen P, Muus P, Duhrsen U, et al. 2007. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood, 110:4123–8. Hillmen P, Young NS, Schubert J, et al. 2006. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med, 355:1233–43. Hitomi Y, Fujii S. 1982. Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor. Int Arch Allergy Appl Immunol, 69:262–7. Hollander W, Colombo MA, Kramsch DM, et al. 1979. Soluble proteins in the human atherosclerotic plaque. With spectral reference to immunoglobulins, C3 complement component, alpha 1 antitrypsin and alpha 2 macroglobulin. Atherosclerosis, 34:391–405. Huber-Lang MS, Riedemann NC, Sarma JV, et al. 2002a. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J, 16:1567–74. Huber-Lang MS, Sarma JV, McGuire SR, et al. 2001. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J, 15:568–70. Huber-Lang MS, Younkin EM, Sarma JV, et al. 2002b. Complement- induced impairment of innate immunity during sepsis. J Immunol, 169:3223–31. Hughes AE, Orr N, Esfandiary H, et al. 2006. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet, 38:1173–7. Hughes-Jones NC, Gardner B. 1978. The reaction between the complement subcomponent C1q, IgG complexes and polyionic molecules. Immunol, 34:459–63. Huugen D, van Esch A, Xiao H, et al. 2007. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int, 71:646–54. Iltumur K, Karabulut A, Toprak G, et al. 2005. Complement activation in acute coronary syndromes. APMIS, 113:167–74. Inagi R, Miyata T, Maeda K, et al. 1991. FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a. Immunol Lett, 27:49–52. Janeway CA, Travers P, Walport M, et al. 1999. The humoral immune response. Immunobiology. The immune system in health and disease. 4th ed. New York: Elsevier Science Ltd/Garland. p. 339–58. Javaid B, Quigg RJ. 2005. Treatment of glomerulonephritis: will we ever have options other than steroids and cytotoxics? Kidney Int, 67:1692–703. Jiang H, Robey FA, Gewurz H. 1992. Localization of sites through which C-reactive protein binds and activates complement to residues 14–26 and 76–92 of the human C1q A chain. J Exp Med, 175:1373–9. Kaplan MH, Volanakis JE. 1974. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin, and sphingomyelin. J Immunol, 112:2135–47. Klein ML, Schultz DW, Edwards A, et al. 1998. Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q. Arch Ophthalmol, 116:1082–8. Klein RJ, Zeiss C, Chew EY, et al. 2005. Complement factor H polymorphism in age-related macular degeneration. Science, 308:385–9. Kostner KM, Fahti RB, Case C, et al. 2006. Inﬂammation, complement activation and endothelial function in stable and unstable coronary artery disease. Clin Chim Acta, 365:129–34. 683